anti-GPC3 CAR-T cell therapy (CRISPR Therapeutics/Roswell Park Cancer Institute)

N/A

Report date: 2025/03/14 16:28:53

Base Information

Drug Nameanti-GPC3 CAR-T cell therapy (CRISPR Therapeutics/Roswell Park Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Biologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCrispr Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Comprehensive Cancer Center Crispr Therapeutics Ag

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A